Skip to main content

RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX)

Tipranks - Tipranks - Fri Feb 13, 6:58AM CST

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Neurocrine, with a price target of $177.00.

Valentine's Day Sale - 70% Off

According to TipRanks, Abrahams is a 4-star analyst with an average return of 6.2% and a 48.71% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Incyte, Regeneron, and Biogen.

In addition to RBC Capital, Neurocrine also received a Buy from Needham’s Ami Fadia in a report issued today. However, on January 26, Morgan Stanley maintained a Hold rating on Neurocrine (NASDAQ: NBIX).

See Insiders’ Hot Stocks on TipRanks >>

Based on Neurocrine’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $794.9 million and a net profit of $209.5 million. In comparison, last year the company earned a revenue of $622.1 million and had a net profit of $129.8 million

Read More on NBIX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).